Amedisys (NASDAQ:AMED) PT Raised to $120.00

Amedisys (NASDAQ:AMED) had its price target raised by Barclays from $115.00 to $120.00 in a research note issued on Thursday, March 21st, BenzingaRatingsTable reports. The firm currently has an “equal weight” rating on the health services provider’s stock. Barclays‘s price objective would indicate a potential downside of 6.70% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. ValuEngine raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 28th. BidaskClub cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 18th. Zacks Investment Research cut shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Monday, January 21st. Finally, Benchmark cut shares of Amedisys from a “buy” rating to a “hold” rating and set a $136.64 target price on the stock. in a research note on Tuesday, February 5th. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Amedisys presently has an average rating of “Hold” and a consensus target price of $124.72.

AMED traded up $2.32 during trading hours on Thursday, reaching $128.62. 181,900 shares of the stock traded hands, compared to its average volume of 415,635. Amedisys has a fifty-two week low of $63.00 and a fifty-two week high of $140.91. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.01. The firm has a market cap of $4.06 billion, a price-to-earnings ratio of 35.43, a PEG ratio of 1.59 and a beta of 1.36.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, February 27th. The health services provider reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.06. Amedisys had a net margin of 7.18% and a return on equity of 25.89%. The business had revenue of $434.38 million for the quarter, compared to analysts’ expectations of $427.75 million. During the same quarter last year, the company earned $0.56 EPS. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. On average, analysts forecast that Amedisys will post 4.05 earnings per share for the current fiscal year.

In other Amedisys news, COO Christopher Gerard sold 2,500 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $118.96, for a total value of $297,400.00. Following the completion of the transaction, the chief operating officer now directly owns 25,731 shares in the company, valued at $3,060,959.76. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David B. Pearce sold 4,370 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $120.01, for a total transaction of $524,443.70. Following the completion of the transaction, the insider now owns 13,129 shares of the company’s stock, valued at $1,575,611.29. The disclosure for this sale can be found here. Insiders sold a total of 8,281 shares of company stock worth $993,393 in the last ninety days. Corporate insiders own 2.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Retirement Systems of Alabama acquired a new stake in Amedisys in the first quarter valued at approximately $4,674,000. Polianta Ltd acquired a new stake in Amedisys in the first quarter valued at approximately $1,774,000. Deutsche Bank AG lifted its stake in Amedisys by 12.1% in the fourth quarter. Deutsche Bank AG now owns 319,075 shares of the health services provider’s stock valued at $37,365,000 after acquiring an additional 34,553 shares during the last quarter. American Century Companies Inc. lifted its stake in Amedisys by 29.2% in the fourth quarter. American Century Companies Inc. now owns 294,471 shares of the health services provider’s stock valued at $34,485,000 after acquiring an additional 66,466 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Amedisys by 23.4% in the fourth quarter. Geode Capital Management LLC now owns 429,999 shares of the health services provider’s stock valued at $50,357,000 after acquiring an additional 81,573 shares during the last quarter. Hedge funds and other institutional investors own 91.81% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: Key terms to understand channel trading

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.